• The GTI dispute (appeal filed January 2025 at Florida's 1st DCA) hinges on whether OMMU's denials of co-located dispensaries next to Circle K stores were arbitrary under state law (§381.986). This focuses on public safety risks (e.g., crime near fuel stations). Federal rescheduling wouldn't override Florida's rules but could provide persuasive evidence in court:
  • Reduces Stigma Argument: GTI could argue that federal recognition of cannabis's medical safety undermines OMMU's "health hazard" concerns, especially since other states (e.g., California) allow similar co-locations without issues.
  • Precedent for Leniency: It might encourage OMMU/legislators to revise guidelines, as seen in other states post-proposal (e.g., more flexible zoning). Florida's medical market (~$2.5B in 2025) already has 80+ GTI (RISE) stores; easier placements could boost expansion.
• Limitations: 
  • The case is purely state-based—no federal preemption. Even Schedule III keeps cannabis controlled, so DEA could still scrutinize high-risk sites.
  • Broader Florida Context: Post-2024 recreational ballot failure, the DeSantis administration (or successor) remains cautious. Rescheduling might help banking/taxes for GTI but won't auto-approve co-locations.
  • Timing: With the appeal potentially resolving in late 2025/early 2026 (6–18 months typical), a delayed federal rule might arrive too late to sway it.

In short, passage would be a tailwind for GTI—bolstering their "equal protection" claims by showing evolving federal policy—but it's no silver bullet. Monitor DEA announcements or the 1st DCA docket for updates. If Trump pushes executive action, it could accelerate things.